Suzanne Chamberland

2.6k total citations · 1 hit paper
38 papers, 2.1k citations indexed

About

Suzanne Chamberland is a scholar working on Molecular Medicine, Molecular Biology and Pharmacology. According to data from OpenAlex, Suzanne Chamberland has authored 38 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Medicine, 15 papers in Molecular Biology and 13 papers in Pharmacology. Recurrent topics in Suzanne Chamberland's work include Antibiotic Resistance in Bacteria (19 papers), Antibiotics Pharmacokinetics and Efficacy (10 papers) and Antimicrobial Resistance in Staphylococcus (6 papers). Suzanne Chamberland is often cited by papers focused on Antibiotic Resistance in Bacteria (19 papers), Antibiotics Pharmacokinetics and Efficacy (10 papers) and Antimicrobial Resistance in Staphylococcus (6 papers). Suzanne Chamberland collaborates with scholars based in Canada, United States and Japan. Suzanne Chamberland's co-authors include Ving J. Lee, Olga Lomovskaya, Roger Léger, Mark S. Warren, Johanne Blais, Scott J. Hecker, Hiroko Ishida, Kazuki Hoshino, Jorge L. Galazzo and May Lee and has published in prestigious journals such as Journal of the American Chemical Society, Clinical Infectious Diseases and Journal of Medicinal Chemistry.

In The Last Decade

Suzanne Chamberland

38 papers receiving 2.0k citations

Hit Papers

Identification and Characterization of Inhibitors of Mult... 2001 2026 2009 2017 2001 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa : Novel Agents for Combination Therapy
    2001 731 citations Olga Lomovskaya, Mark S. Warren et al. Antimicrobial Agents and Chemotherapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suzanne Chamberland Canada 21 1.3k 910 691 426 334 38 2.1k
Kazuki Hoshino Japan 25 1.8k 1.4× 1.4k 1.5× 949 1.4× 520 1.2× 405 1.2× 46 2.9k
Thomas D. Gootz United States 36 1.5k 1.1× 1.3k 1.4× 1.2k 1.7× 661 1.6× 490 1.5× 60 3.4k
Philip Lister United States 24 1.7k 1.3× 985 1.1× 853 1.2× 591 1.4× 218 0.7× 50 2.6k
Shizuko Iyobe Japan 25 1.8k 1.4× 1.0k 1.2× 829 1.2× 299 0.7× 279 0.8× 73 2.4k
Stephen Rittenhouse United States 26 812 0.6× 801 0.9× 607 0.9× 339 0.8× 458 1.4× 43 2.2k
Patrick Plésiat France 15 1.3k 1.0× 767 0.8× 363 0.5× 269 0.6× 215 0.6× 25 2.0k
D P Bonner United States 30 929 0.7× 764 0.8× 1.1k 1.6× 669 1.6× 824 2.5× 72 2.9k
Susan M. Seo United States 21 779 0.6× 926 1.0× 334 0.5× 275 0.6× 991 3.0× 28 1.9k
Cynthia H. O'Callaghan United Kingdom 17 1.1k 0.9× 988 1.1× 921 1.3× 583 1.4× 415 1.2× 24 2.7k
Michael D. Huband United States 30 1.5k 1.1× 683 0.8× 986 1.4× 719 1.7× 708 2.1× 113 2.8k

Countries citing papers authored by Suzanne Chamberland

Since Specialization
Citations

This map shows the geographic impact of Suzanne Chamberland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Chamberland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Chamberland more than expected).

Fields of papers citing papers by Suzanne Chamberland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Chamberland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Chamberland. The network helps show where Suzanne Chamberland may publish in the future.

Co-authorship network of co-authors of Suzanne Chamberland

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne Chamberland. A scholar is included among the top collaborators of Suzanne Chamberland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne Chamberland. Suzanne Chamberland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Séguin, David Lalonde, Suzanne Chamberland, Jean‐François Lucier, et al.. (2023). Staphylococcus aureus Small-Colony Variants from Airways of Adult Cystic Fibrosis Patients as Precursors of Adaptive Antibiotic-Resistant Mutations. Antibiotics. 12(6). 1069–1069. 9 indexed citations
2.
Brouillette, Éric, Suzanne Chamberland, Céline Ster, et al.. (2023). Effective Treatment of Staphylococcus aureus Intramammary Infection in a Murine Model Using the Bacteriophage Cocktail StaphLyse™. Viruses. 15(4). 887–887. 15 indexed citations
3.
Murza, Alexandre, et al.. (2023). From garden to lab: C-3 chemical modifications of tomatidine unveil broad-spectrum ATP synthase inhibitors to combat bacterial resistance. European Journal of Medicinal Chemistry. 262. 115886–115886. 3 indexed citations
4.
Brouillette, Éric, et al.. (2021). Secondary Staphylococcus aureus intramammary colonization is reduced by non-aureus staphylococci exoproducts. Microbes and Infection. 24(1). 104879–104879. 6 indexed citations
5.
Chamberland, Suzanne, Pierre‐Étienne Jacques, Sébastien Rodrigue, et al.. (2020). Bactericidal Activity of the Bacterial ATP Synthase Inhibitor Tomatidine and the Combination of Tomatidine and Aminoglycoside Against Persistent and Virulent Forms of Staphylococcus aureus. Frontiers in Microbiology. 11. 805–805. 16 indexed citations
6.
Boojamra, Constantine G., Rémy C. Lemoine, Johanne Blais, et al.. (2003). Synthetic dihydropacidamycin antibiotics. Bioorganic & Medicinal Chemistry Letters. 13(19). 3305–3309. 28 indexed citations
7.
Watkins, William J., Roger Léger, Thomas E. Renau, et al.. (2003). The relationship between physicochemical properties, In vitro activity and pharmacokinetic profiles of analogues of diamine-Containing efflux pump inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(23). 4241–4244. 64 indexed citations
8.
Renau, Thomas E., Roger Léger, Eric M. Flamme, et al.. (2003). Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorganic & Medicinal Chemistry Letters. 13(16). 2755–2758. 76 indexed citations
9.
Boojamra, Constantine G., Rémy C. Lemoine, Julie C. Lee, et al.. (2001). Stereochemical Elucidation and Total Synthesis of Dihydropacidamycin D, a Semisynthetic Pacidamycin. Journal of the American Chemical Society. 123(5). 870–874. 43 indexed citations
10.
Lomovskaya, Olga, Mark S. Warren, Angela Lee, et al.. (2001). Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa : Novel Agents for Combination Therapy. Antimicrobial Agents and Chemotherapy. 45(1). 105–116. 731 indexed citations breakdown →
11.
Renau, Thomas E., Roger Léger, Eric M. Flamme, et al.. (2001). Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorganic & Medicinal Chemistry Letters. 11(5). 663–667. 50 indexed citations
12.
Galazzo, Jorge L., Andrew L. Staley, Julie C. Lee, et al.. (2001). Microbial fermentation-derived inhibitors of efflux-pump-mediated drug resistance. Il Farmaco. 56(1-2). 81–85. 82 indexed citations
13.
Lee, Jean C., et al.. (2000). New Pacidamycins Produced by Streptomyces coeruleorubidus, NRRL 18370.. The Journal of Antibiotics. 53(12). 1405–1410. 35 indexed citations
14.
Hecker, Scott J., Tomasz Glinka, Aesop Cho, et al.. (2000). Discovery of RWJ-54428 (MC-02,479), a New Cephalosporin Active Against Resistant Gram-positive Bacteria.. The Journal of Antibiotics. 53(11). 1272–1281. 16 indexed citations
15.
Renau, Thomas E., Roger Léger, Eric M. Flamme, et al.. (1999). Inhibitors of Efflux Pumps in Pseudomonas aeruginosa Potentiate the Activity of the Fluoroquinolone Antibacterial Levofloxacin. Journal of Medicinal Chemistry. 42(24). 4928–4931. 219 indexed citations
16.
Chamberland, Suzanne, et al.. (1992). Antibiotic Susceptibility Profiles of 941 Gram-Negative Bacteria Isolated from Septicemic Patients Throughout Canada. Clinical Infectious Diseases. 15(4). 615–628. 55 indexed citations
17.
Chamberland, Suzanne, Herbert A. Kirst, & William L. Current. (1991). Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay. Antimicrobial Agents and Chemotherapy. 35(5). 903–909. 46 indexed citations
18.
Chamberland, Suzanne & William L. Current. (1991). Use of Mouse Macrophage Cell Lines for In Vitro Propagation of Toxoplasma gondii RH Tachyzoites. Experimental Biology and Medicine. 197(2). 150–157. 12 indexed citations
19.
Chamberland, Suzanne, François Malouin, Harvey Rabin, et al.. (1990). Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency. Journal of Antimicrobial Chemotherapy. 25(6). 995–1010. 27 indexed citations
20.
Schryvers, Anthony B., et al.. (1987). Mechanism of Pseudomonas aeruginosa persistence during treatment with broad-spectrum cephalosporins of lung infections in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy. 31(9). 1438–1439. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazuki Hoshino Breakdown of academic impact, for papers by Thomas D. Gootz Breakdown of academic impact, for papers by Philip Lister Breakdown of academic impact, for papers by Shizuko Iyobe Breakdown of academic impact, for papers by Stephen Rittenhouse Breakdown of academic impact, for papers by Patrick Plésiat Breakdown of academic impact, for papers by D P Bonner Breakdown of academic impact, for papers by Susan M. Seo Breakdown of academic impact, for papers by Cynthia H. O'Callaghan Breakdown of academic impact, for papers by Michael D. Huband
Rankless by CCL
2026